Google Translate Disclaimer

A number of pages on the Government of Saskatchewan`s web site have been professionally translated in French. These translations are identified by a yellow text box that resembles the link below and can be found in the right hand rail of the page. The home page for French-language content on this site can be found here:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

The results of software-based translation do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos, and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

U of S VIDO-InterVac develops vaccine for devastating pig virus

By Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) Staff

Photo courtesy of VIDO-InterVac and Debra Marshall.
In under two years, the University of Saskatchewan’s Vaccine and Infectious Disease-International Vaccine Centre (VIDO-InterVac) scientists developed and tested a prototype vaccine that could protect the North American swine industry from a virus that has killed more than eight million pigs and cost more than $400 million in lost income since 2013.

The Porcine Epidemic Diarrhea Virus (PEDv) hit the United States in 2013 and spread to Canada in 2014. It was first discovered in Europe, and has become increasingly problematic in Asian countries. Occurring only in pigs, PEDv can kill up to 100 per cent of infected piglets and survives well in the environment, making it a significant threat to the swine industry. PEDv is a coronavirus, a virus group, which includes important emerging human diseases such as SARS and MERS.

In the fall of 2013, VIDO-InterVac quickly launched a vaccine development project. A team of scientists, technicians and veterinarians, led by Dr. Volker Gerdts, established the infection in piglets and tested several vaccine prototypes using VIDO-InterVac’s high containment facility – a world-class facility built with financial support from the Government of Canada, Government of Saskatchewan and City of Saskatoon. The most promising candidate was found to protect more than 95 per cent of piglets.

Photo courtesy of VIDO-Intervac.
“This is a perfect example of why InterVac was constructed – it is one of the only facilities available internationally with the capacity to conduct vaccine development and testing on this scale for emerging infectious diseases. It helps Canada remain prepared to quickly respond to outbreaks like this,” said VIDO-InterVac director Andrew Potter.

With support from the Saskatchewan Pork Development Board (SaskPork), the Canadian Swine Health Alliance and the Government of Saskatchewan Agriculture Development Fund (ADF), a Growing Forward 2 program, the vaccine candidate was tested in three commercial units in Saskatchewan and subsequently licensed to Huvepharma, a human and animal health company out of Europe, which plans to develop the technology for commercial production in North America.

The vaccine has also received two awards: SaskPork’s Award of Distinction for Research Innovation, and Saskatoon Regional Economic Development Authority’s Science, Technology, Innovation and Collaboration Project Award.

We need your feedback to improve Help us improve